Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
Top Page
Blueprint Medicines
(NASDAQ:BPMC)52Neutral
Positive Factors
Financial Performance
Ayvakit generated $144.1MM in sales revenue across all indications, showing significant quarter-over-quarter and year-over-year growth.
Investment Potential
Blueprint Medicines Corporation shares represent an attractive investment opportunity, especially given the recent weakness, with potential upside in stock value.
Negative Factors
Safety Concerns
A lead investigator suggested that up to 5% of patients at the 50 mg dose in PIONEER may have had Gr3 LFT elevations.
Blueprint Medicines (BPMC) vs. S&P 500 (SPY)
Market Cap
$5.66B
Dividend YieldN/A
Average Volume (3M)1.03M
Price to Earnings (P/E)―
Beta (1Y)1.57
Revenue Growth104.04%
EPS Growth87.80%
CountryUS
Employees649
SectorHealthcare
Sector Strength74
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.07
Shares Outstanding63,906,010
10 Day Avg. Volume977,173
30 Day Avg. Volume1,032,061
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.12
Price to Cash Flow (P/CF)-48.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$130.93Price Target Upside50.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Blueprint Medicines Business Overview & Revenue Model
Company DescriptionBlueprint Medicines Corporation (BPMC) is a biopharmaceutical company focused on developing targeted therapies to improve the lives of patients with genomically defined cancers, rare diseases, and cancer immunotherapy. Operating within the biotechnology and pharmaceutical sectors, the company leverages its proprietary scientific platform to design and develop highly selective kinase inhibitors. Its core products include FDA-approved therapies such as AYVAKIT/AYVAKYT (avapritinib) for certain types of gastrointestinal stromal tumors (GIST) and systemic mastocytosis, as well as other investigational therapies in clinical development.
How the Company Makes MoneyBlueprint Medicines generates revenue primarily through the sales of its approved therapies, such as AYVAKIT/AYVAKYT, which are marketed for specific indications in the United States and Europe. Additionally, the company earns revenue through collaboration and licensing agreements with other pharmaceutical companies, which may include upfront payments, milestone payments, and royalties based on the sales of partnered products. Significant partnerships, such as those with Genentech and CStone Pharmaceuticals, contribute to its earnings by expanding the reach and development of its products in various markets. Moreover, Blueprint Medicines invests in research and development to continually innovate and expand its pipeline of targeted therapies, which supports long-term revenue growth.
Blueprint Medicines Financial Statement Overview
Summary
Blueprint Medicines shows promising revenue growth but faces profitability challenges, with persistent losses impacting financial stability. The balance sheet is improving, which suggests a more sustainable financial position, yet the high liabilities and negative cash flows highlight the need for continued revenue growth and cost control to achieve long-term financial health.Income Statement
Blueprint Medicines has experienced a significant increase in revenue over the past year, with a growth rate of over 100% from 2023 to 2024. However, profitability remains a major concern as evidenced by negative EBIT and net income margins, indicating ongoing operational challenges. The gross profit margin remains strong, suggesting effective cost management at the production level, but overall financial performance is hindered by substantial operating expenses.45
Neutral
Balance Sheet
The balance sheet reflects a moderate level of financial health. The debt-to-equity ratio has improved due to a reduction in total debt and an increase in stockholders’ equity, indicating a more balanced capital structure. The equity ratio is reasonable, showing a decent proportion of assets financed by equity. However, the company’s liabilities remain significant, posing potential risks if revenue growth does not continue.60
Neutral
Cash Flow
Cash flow analysis reveals challenges, with negative free cash flow indicating insufficient cash from operations to cover capital expenditures. However, there has been a significant improvement in operating cash flow from 2023 to 2024, reflecting better operational cash management. The operating cash flow to net income ratio is negative, highlighting persistent profitability issues.50
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 508.82M | 249.38M | 204.04M | 180.08M | 793.74M | Gross Profit |
| 488.66M | 236.58M | 186.22M | 162.15M | 793.31M | EBIT |
| -212.04M | -486.28M | -549.25M | -648.46M | 302.15M | EBITDA |
| -212.04M | -470.36M | -515.41M | -628.30M | 308.71M | Net Income Common Stockholders |
| -67.09M | -506.98M | -557.52M | -644.09M | 313.88M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 615.49M | 710.64M | 1.08B | 1.03B | 1.55B | Total Assets |
| 1.18B | 1.05B | 1.35B | 1.25B | 1.72B | Total Debt |
| 126.05M | 774.12M | 242.45M | 111.41M | 89.60M | Net Debt |
| 24.04M | 702.84M | 122.74M | -98.54M | -595.03M | Total Liabilities |
| 881.15M | 918.64M | 835.23M | 281.49M | 248.31M | Stockholders Equity |
| 298.67M | 130.61M | 514.68M | 970.74M | 1.47B |
| Cash Flow | Free Cash Flow | |||
| -197.22M | -452.91M | -511.20M | -559.89M | 383.88M | Operating Cash Flow |
| -192.59M | -436.85M | -502.28M | -298.65M | 387.04M | Investing Cash Flow |
| -47.50M | 274.04M | -149.54M | -225.86M | -434.25M | Financing Cash Flow |
| 273.11M | 119.22M | 561.81M | 50.72M | 617.76M |
Blueprint Medicines Technical Analysis
Negative
87.12
Price Trends
98.98
Negative
95.67
Negative
97.82
Negative
Market Momentum
-3.81
Positive
34.22
Neutral
25.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BPMC, the sentiment is Negative. The current price of 87.12 is below the 20-day moving average (MA) of 94.16, below the 50-day MA of 98.98, and below the 200-day MA of 97.82, indicating a bearish trend. The MACD of -3.81 indicates Positive momentum. The RSI at 34.22 is Neutral, neither overbought nor oversold. The STOCH value of 25.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BPMC.
Blueprint Medicines Risk Analysis
Blueprint Medicines disclosed 71 risk factors in its most recent earnings report. Blueprint Medicines reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Blueprint Medicines Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $10.82B | 21.56 | 23.13% | ― | 18.49% | 176.71% | |
70 Outperform | $38.07B | 46.58 | -7.20% | ― | 101.07% | 51.16% | |
52 Neutral | $5.66B | ― | -31.26% | ― | 104.04% | 87.80% | |
49 Neutral | $7.05B | 0.34 | -55.09% | 2.46% | 25.27% | -3.43% | |
49 Neutral | $39.33M | ― | 60.38% | ― | 16.15% | 59.81% | |
45 Neutral | $621.81M | ― | -42.91% | ― | ― | 2.90% | |
45 Neutral | $308.33M | ― | -28.28% | ― | ― | 6.80% |
* Healthcare Sector Average
Performance Comparison
BPMC
Blueprint Medicines
87.12
-2.35
-2.63%
EXEL
Exelixis
38.58
16.12
71.77%
FGEN
FibroGen
0.37
-1.34
-78.36%
KURA
Kura Oncology
7.53
-15.29
-67.00%
ARGX
Argenx Se
594.21
209.21
54.34%
TERN
Terns Pharmaceuticals
3.49
-3.94
-53.03%
Blueprint Medicines Earnings Call Summary
Earnings Call Date: Feb 13, 2025 | % Change Since: -15.87% | Next Earnings Date: May 1, 2025
Earnings Call Sentiment Positive
The earnings call was predominantly positive, with strong revenue growth and market expansion for AYVAKIT, successful international progress, promising development of BLU-808, and financial discipline. However, some challenges in Q1 2025 and a heavy reliance on the U.S. market were noted.Highlights
AYVAKIT Revenue Growth
In 2024, AYVAKIT achieved $479 million in product revenue, representing impressive annual growth of 135%. The company expects AYVAKIT to achieve $680 million to $710 million in revenue in 2025, with a projected 45% growth rate at the midpoint.
Increased Market Opportunity
Blueprint Medicines identified a larger SM market than previously thought, with new epidemiology data suggesting a twofold increase in potential SM patients in the U.S., from approximately 30,000 to 60,000 patients.
International Expansion
The company obtained ISM pricing for AYVAKIT in Germany and plans to launch in additional European markets, with significant international revenue growth expected.
BLU-808 Clinical Development
Positive healthy volunteer data for BLU-808 showing a wide therapeutic index and promising pharmacodynamics, with proof-of-concept studies planned for multiple allergic and inflammatory diseases.
Financial Discipline
Blueprint Medicines reported a significant reduction in cash burn, with operating expenses reduced in 2024 compared to 2023, and expects operating cash burn to continue to decline in 2025.
Lowlights
Q1 2025 Revenue Challenges
The company anticipates challenges in Q1 2025 due to insurance reverification process, potential FX headwinds, and fewer ordering days from major customers, which might affect short-term revenue performance.
Dependency on U.S. Market
While international growth is expected, the U.S. market remains the primary driver of revenue, indicating potential risk if U.S. market dynamics change.
Company Guidance
During the Blueprint Medicines 4Q and FY 2024 earnings call, the company provided robust guidance for 2025, projecting AYVAKIT's revenue to reach $680 million to $710 million, reflecting an impressive 45% growth at the midpoint. This follows a notable annual growth of 135% in 2024, with product revenue hitting $479 million. The company's leadership anticipates a long-term target of $2 billion in revenue by 2030, bolstered by a growing market for systemic mastocytosis treatment. They emphasized the low penetration of AYVAKIT among currently diagnosed patients, suggesting substantial room for growth. Additionally, the company expects the systemic mastocytosis franchise, anchored by AYVAKIT, to eventually reach a peak value of $4 billion. To achieve these goals, Blueprint Medicines plans to expand its commercial and medical field infrastructure, invest in market-building initiatives, and advance its pipeline, including the next-generation KIT D816V inhibitor, elenestinib, and the promising BLU-808, aimed at a range of mast cell-mediated allergic inflammatory diseases.Blueprint Medicines Corporate Events
Business Operations and StrategyFinancial Disclosures
Blueprint Medicines Highlights 2024 Achievements and Future Growth
Positive
Jan 13, 2025
Blueprint Medicines Corporation announced updates to its corporate presentation for the investment community, emphasizing its growth strategies and operational excellence. The company highlighted its achievements in 2024, including significant revenue growth for AYVAKIT, the expansion of its global reach, and advancements in drug development, positioning itself for continued innovation and market expansion in 2025.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.